A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
- Authors
- Kim, Tae-Yong; Han, Hye Sook; Lee, Keun-Wook; Zang, Dae Young; Rha, Sun Young; Park, Young Lee; Kim, Jin-Soo; Lee, Kyung-Hun; Park, Se Hoon; Song, Eun-Kee; Jung, Soo-A; Lee, NaMi; Kim, Yeul Hong; Cho, Jae Yong; Bang, Yung-Jue
- Issue Date
- 11월-2019
- Publisher
- SPRINGER
- Keywords
- Chemotherapy; Gastric cancer; HER2; Poziotinib; Trastuzumab
- Citation
- GASTRIC CANCER, v.22, no.6, pp.1206 - 1214
- Indexed
- SCIE
SCOPUS
- Journal Title
- GASTRIC CANCER
- Volume
- 22
- Number
- 6
- Start Page
- 1206
- End Page
- 1214
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/62115
- DOI
- 10.1007/s10120-019-00958-4
- ISSN
- 1436-3291
- Abstract
- Background Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicenter, open-label, phase I/II study determined the maximum tolerated dose (MTD) and evaluated the safety and efficacy of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer (GC). Methods Patients with HER2-positive GC previously treated with one line of chemotherapy received oral poziotinib (8 mg or 12 mg) once daily for 14 days, followed by 7 days off. Paclitaxel (175 mg/m(2) infusion) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg infusion) were administered concomitantly with poziotinib on day 1 every 3 weeks. Results In the phase I part, 12 patients were enrolled (7 at dose level 1, 5 at dose level 2). One patient receiving poziotinib 8 mg and 2 receiving poziotinib 12 mg had dose-limiting toxicities (DLTs); all DLTs were grade 4 neutropenia, one with fever. The most common poziotinib-related adverse events were diarrhea, rash, stomatitis, pruritus and loss of appetite. The MTD of poziotinib was determined to be 8 mg/day and this was used in the phase II part which enrolled 32 patients. Two patients (6.3%) had complete responses and 5 (15.6%) had partial responses (objective response rate 21.9%). Median progression-free survival and overall survival were 13.0 weeks (95% CI 9.8-21.9) and 29.5 weeks (95% CI 17.9-59.2), respectively. Conclusions The MTD of poziotinib combined with paclitaxel and trastuzumab was 8 mg/day. This combination yielded promising anti-tumor efficacy with manageable toxicity in previously treated patients with HER2-positive GC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.